Researchers have detected distinct immune system antibody patterns in blood samples taken up to ten years before patients developed inflammatory bowel disease, according to a presentation at the UEG Week 2026 medical congress.
Immune System Patterns Found Years Before Diagnosis
Chronic inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, often trigger long searches for a cause only after physical symptoms appear. Investigators analyzed 2,000 blood samples from 500 individuals to determine whether the body sends earlier biological warnings. The cohort included 200 people who later developed Crohn’s disease, 200 who developed ulcerative colitis, and 100 healthy control subjects.
The samples spanned multiple intervals, including roughly ten, four, and two years prior to clinical diagnosis, as well as samples from the time of disease onset. Medical Xpress reported that scientists tracked specific antibodies in the blood to see how the immune defense reacted to pathogens and other biological structures. The team found distinct antibody profiles that separated future patients from healthy participants well before clinical signs emerged.
Computer Models Predict Future Risk
Using a machine learning model, researchers distinguished future patients from healthy control subjects based on these early immune markers. For blood samples collected approximately a decade before diagnosis, the statistical accuracy metric reached 0.90 for Crohn’s disease and 0.84 for ulcerative colitis, where values closer to 1.0 indicate higher predictive accuracy.
Lead investigator Dr. Arno Bourgonje noted that the antibody profiles also provided clues about disease severity. It is fascinating to see that a complicated course of Crohn’s disease at diagnosis is connected with a certain antibody profile—and that years before the first clinical symptoms,
Dr. Bourgonje stated. The data indicate these immune signatures develop long before clinical onset rather than serving merely as a byproduct of active inflammation.
Antibody patterns require validation before clinical use
Inflammatory bowel diseases feature a misdirected immune response that causes persistent inflammation along the digestive tract, typically following a relapsing-remitting course that disrupts daily life. While the discovery points toward potential screening tools, researchers emphasize that the findings do not yet allow for reliable individual predictions.
Before any clinical blood test can enter practice, the identified antibody patterns require validation across independent and diverse patient cohorts. Investigators must also determine whether an antibody screening panel adds meaningful clinical value beyond established risk factors and standard diagnostic workups.
What are inflammatory bowel diseases and their detection?
What specific conditions are classified as inflammatory bowel diseases?
The category primarily includes Crohn’s disease and ulcerative colitis, both of which involve chronic inflammation of the digestive tract driven by aberrant immune activity.
How far in advance did the study detect immune signatures?
Computer models successfully differentiated future patients from healthy controls using blood samples collected up to ten years prior to an eventual clinical diagnosis.
Are these antibody tests currently available for clinical use?
No clinical test exists yet. The findings stem from a research presentation at UEG Week 2026, and the identified patterns require further validation in independent populations.
Worth a look